Literature DB >> 31372667

Differential expression and release of exosomal miRNAs by human islets under inflammatory and hypoxic stress.

Prathab Balaji Saravanan1, Srividya Vasu2, Gumpei Yoshimatsu2, Carly M Darden2, Xuan Wang2, Jinghua Gu2, Michael C Lawrence3, Bashoo Naziruddin4.   

Abstract

AIMS/HYPOTHESIS: Pancreatic islets produce non-coding microRNAs (miRNAs) that regulate islet cell function and survival. Our earlier investigations revealed that human islets undergo significant damage due to various types of stresses following transplantation and release miRNAs. Here, we sought to identify and validate exosomal miRNAs (exo-miRNAs) produced by human islets under conditions of cellular stress, preceding loss of cell function and death. We also aimed to identify islet stress signalling pathways targeted by exo-miRNAs to elucidate potential regulatory roles in islet cell stress.
METHODS: Human islets were subjected to proinflammatory cytokine and hypoxic cell stress and miRNA from exosomes was isolated for RNA sequencing and analysis. Stress-induced exo-miRNAs were evaluated for kinetics of expression and release by intact islets for up to 48 h exposure to cytokines and hypoxia. A subset of stress-induced exo-miRNAs were assessed for recovery and detection as biomarkers of islet cell stress in a diabetic nude mouse xenotransplant model and in patients undergoing total pancreatectomy with islet auto-transplantation (TPIAT). Genes and signalling pathways targeted by stress-induced exo-miRNAs were identified by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and direct interactions of miRNAs with downstream signalling targets were validated in human islet cells using the miRNA Tests for Read Analysis and Prediction (MirTrap) system.
RESULTS: Global exo-miRNA sequencing revealed that 879 miRNA species were released from human islets and 190 islet exo-miRNAs were differentially expressed in response to proinflammatory cytokines, hypoxia or both. Release of exo-miRNAs hsa-miR-29b-3p and hsa-miR-216a-5p was detected within 6 h of exposure to cytokines and hypoxia. The remaining subset of stress-induced exo-miRNAs, including hsa-miR-148a-3p and islet cell damage marker hsa-miR-375, showed delayed release at 24-48 h, correlating with apoptosis and cell death. Stress and damage exo-miRNAs were significantly elevated in the circulation in human-to-mouse xenotransplant models and in human transplant recipients. Elevated blood exo-miRNAs negatively correlated with post-transplant islet function based on comparisons of stress and damage exo-miRNA indices with Secretory Unit of Islet Transplant Objects (SUITO) indices. KEGG analysis and further validation of exo-miRNA targets by MirTrap analysis revealed significant enrichment of islet mRNAs involved in phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase signalling pathways. CONCLUSIONS/
INTERPRETATION: The study identifies exo-miRNAs differentially expressed and released by islets in response to damage and stress. These exo-miRNAs could serve as potential biomarkers for assessing islet damage and predicting outcomes in islet transplantation. Notably, exo-miRNAs 29b-3p and 216a-5p could be detected in islets prior to damage-released miRNAs and indicators of cellular apoptosis and death. Thus, these stress-induced exo-miRNAs may have potential diagnostic value for detecting early islet stress prior to progressive loss of islet cell mass and function. Further investigations are warranted to investigate the utility of these exo-miRNAs as early indicators of islet cell stress during prediabetic conditions.

Entities:  

Keywords:  Cellular stress; Exosomal miRNA; Islet cell damage; Islet transplantation; PI3K–Akt signalling pathway

Mesh:

Substances:

Year:  2019        PMID: 31372667     DOI: 10.1007/s00125-019-4950-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  57 in total

1.  Anti-apoptotic activity of human matrix metalloproteinase-2 attenuates diabetes mellitus.

Authors:  Kota Nishihama; Taro Yasuma; Yutaka Yano; Corina N D' Alessandro-Gabazza; Masaaki Toda; Josephine A Hinneh; Prince Baffour Tonto; Atsuro Takeshita; Toshiaki Totoki; Rumi Mifuji-Moroka; Tetsu Kobayashi; Motoh Iwasa; Yoshiyuki Takei; John Morser; Isaac Cann; Esteban C Gabazza
Journal:  Metabolism       Date:  2018-01-31       Impact factor: 8.694

2.  Primary Human and Rat β-Cells Release the Intracellular Autoantigens GAD65, IA-2, and Proinsulin in Exosomes Together With Cytokine-Induced Enhancers of Immunity.

Authors:  Chiara Cianciaruso; Edward A Phelps; Miriella Pasquier; Romain Hamelin; Davide Demurtas; Mohamed Alibashe Ahmed; Lorenzo Piemonti; Sachiko Hirosue; Melody A Swartz; Michele De Palma; Jeffrey A Hubbell; Steinunn Baekkeskov
Journal:  Diabetes       Date:  2016-11-21       Impact factor: 9.461

Review 3.  Circulating microRNAs as novel biomarkers for diabetes mellitus.

Authors:  Claudiane Guay; Romano Regazzi
Journal:  Nat Rev Endocrinol       Date:  2013-04-30       Impact factor: 43.330

4.  Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation.

Authors:  J A SoRelle; T Itoh; H Peng; M A Kanak; K Sugimoto; S Matsumoto; M F Levy; M C Lawrence; B Naziruddin
Journal:  Diabetologia       Date:  2013-01-15       Impact factor: 10.122

5.  Stress-Induced MicroRNA-708 Impairs β-Cell Function and Growth.

Authors:  Júlia Rodríguez-Comas; Alba Moreno-Asso; Juan Moreno-Vedia; Mercè Martín; Carlos Castaño; Anna Marzà-Florensa; Xavier Bofill-De Ros; Joan Mir-Coll; Joel Montané; Cristina Fillat; Rosa Gasa; Anna Novials; Joan-Marc Servitja
Journal:  Diabetes       Date:  2017-10-02       Impact factor: 9.461

6.  Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat.

Authors:  Jonathan Lou S Esguerra; Caroline Bolmeson; Corrado M Cilio; Lena Eliasson
Journal:  PLoS One       Date:  2011-04-07       Impact factor: 3.240

Review 7.  MicroRNAs as stress regulators in pancreatic beta cells and diabetes.

Authors:  Mary P LaPierre; Markus Stoffel
Journal:  Mol Metab       Date:  2017-07-18       Impact factor: 7.422

8.  The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis.

Authors:  Martijn van de Bunt; Kyle J Gaulton; Leopold Parts; Ignasi Moran; Paul R Johnson; Cecilia M Lindgren; Jorge Ferrer; Anna L Gloyn; Mark I McCarthy
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

9.  Urinary exosomal microRNAs in incipient diabetic nephropathy.

Authors:  Federica Barutta; Marinella Tricarico; Alessandro Corbelli; Laura Annaratone; Silvia Pinach; Serena Grimaldi; Graziella Bruno; Daniela Cimino; Daniela Taverna; Maria Chiara Deregibus; Maria Pia Rastaldi; Paolo Cavallo Perin; Gabriella Gruden
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

10.  MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity.

Authors:  Apolline Salama; Nolwenn Fichou; Marie Allard; Laurence Dubreil; Laurence De Beaurepaire; Alexis Viel; Dominique Jégou; Steffi Bösch; Jean-Marie Bach
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more
  19 in total

1.  Mesenchymal stem cells-derived exosomes ameliorate nucleus pulposus cells apoptosis via delivering miR-142-3p: therapeutic potential for intervertebral disc degenerative diseases.

Authors:  Lifan Zhu; Yuhui Shi; Ling Liu; Huan Wang; Pengcheng Shen; Huilin Yang
Journal:  Cell Cycle       Date:  2020-06-17       Impact factor: 4.534

Review 2.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

3.  Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes.

Authors:  Baoyan Fan; Chao Li; Alexandra Szalad; Lei Wang; Wanlong Pan; Ruilan Zhang; Michael Chopp; Zheng Gang Zhang; Xian Shuang Liu
Journal:  Diabetologia       Date:  2019-11-19       Impact factor: 10.122

4.  Inhibition of Circulating Exosomal miRNA-20b-5p Accelerates Diabetic Wound Repair.

Authors:  Kai Chen; Tao Yu; Xin Wang
Journal:  Int J Nanomedicine       Date:  2021-01-14

Review 5.  The Role of Extracellular Vesicles in β-Cell Function and Viability: A Scoping Review.

Authors:  Stephanie Chidester; Alicia A Livinski; Anne F Fish; Paule V Joseph
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-11       Impact factor: 5.555

6.  Effect of diabetes on exosomal miRNA profile in patients with obesity.

Authors:  Hyoshik Kim; Yun-Ui Bae; Haekyung Lee; Hyoungnae Kim; Jin Seok Jeon; Hyunjin Noh; Dong Cheol Han; Dong Won Byun; Sang Hyun Kim; Hyeong Kyu Park; Seongho Ryu; Soon Hyo Kwon
Journal:  BMJ Open Diabetes Res Care       Date:  2020-09

Review 7.  Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications.

Authors:  Francesco Prattichizzo; Giulia Matacchione; Angelica Giuliani; Jacopo Sabbatinelli; Fabiola Olivieri; Paola de Candia; Valeria De Nigris; Antonio Ceriello
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 8.  Extracellular vesicles-incorporated microRNA signature as biomarker and diagnosis of prediabetes state and its complications.

Authors:  Nicoleta Alexandru; Anastasia Procopciuc; Alexandra Vîlcu; Ioana Karla Comariţa; Elisabeta Bӑdilӑ; Adriana Georgescu
Journal:  Rev Endocr Metab Disord       Date:  2021-06-18       Impact factor: 6.514

9.  MicroRNA-29b-3p Promotes Human Retinal Microvascular Endothelial Cell Apoptosis via Blocking SIRT1 in Diabetic Retinopathy.

Authors:  Yong Zeng; Zekai Cui; Jian Liu; Jiansu Chen; Shibo Tang
Journal:  Front Physiol       Date:  2020-01-29       Impact factor: 4.566

Review 10.  MicroRNA Signatures as Future Biomarkers for Diagnosis of Diabetes States.

Authors:  Srividya Vasu; Kenjiro Kumano; Carly M Darden; Irum Rahman; Michael C Lawrence; Bashoo Naziruddin
Journal:  Cells       Date:  2019-11-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.